Biogen Idec is a pharmaceutical company specializing in drugs for autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and Idec Pharmaceuticals of San Diego, California.
Biogen Idec is headquartered in Kendall Square in Cambridge, Massachusetts, and operates research and development facilities in Cambridge and San Diego. Biogen Idec operates a manufacturing facility in Research Triangle Park, North Carolina. The company employs about 4,000 people.
Biogen Idec's principal competitors include Genentech (with which the company has a marketing partnership for the cancer drug Rituxan), Amgen, Serono, and Elan Pharmaceuticals. As of 2003, Biogen Idec derives most of its income from sales of multiple sclerosis treatment Avonex and partnership royalties on Rituxan.